Introduction
The prevalence of learning disability in the general population is reported as 3.7 per 1000 of the population. 1 Epilepsy is common in those with a learning disability (LD) and its frequency increases progressively with more severe intellectual impairment. Overall lifetime prevalence of epilepsy in those with mild to moderate learning disability (IQ 35-70) has been estimated at 15% whilst in those with severe to profound learning disability (IQ less than 50) a prevalence of 30% has been reported. 2 Prognosis for seizure control in people with learning disability and epilepsy has been poorer than for those with epilepsy without learning disability. 3 These higher rates of inadequately controlled epilepsy bring increased rates of morbidity and also mortality. 4 In a Swedish study of over 1400 patients with learning disability, followed up for seven years, the standardised mortality ratio (SMR) for those with learning disability without epilepsy was 1.6 but the SMR increased to 5.0 in those with concomitant epilepsy. 5 Despite the fact that epilepsy is a serious problem in those who have a learning disability, there is a lack of randomised control trial evidence-based descriptions of optimal treatment approaches in this clinical group. 6, 13 Within the UK, epilepsy management in those with LD has been provided by various combinations of primary care, specialist epilepsy and neurology services as well as learning disability mental health services and social care agencies, with no clear indications as to which service provides what treatment to any particular individual or why a particular care pathway was followed. The recent Epilepsy in those with learning disability (LD) is currently managed by various health agencies with no obvious criteria for selecting particular care pathways and limited evidence-based descriptions of optimal treatment. The aim of this study was to examine relationships between management strategies and clinical outcomes in a community-based cohort of individuals with epilepsy and LD. The results may inform epilepsy management directly and contribute to an evidence base to support development of formal clinical trials. An attempt was made to recruit all individuals with epilepsy and LD known to community LD health services in one geographic area. However, those with profound LD were under-represented in the final sample. Information relating to the epilepsy, the severity of the LD, comorbidities and epilepsy management were obtained retrospectively both from the clinical notes and from interviews with carers and clinicians.
We recruited 183 individuals of whom 33% had no reported seizures in the previous three months whilst 12% recorded more than 20 seizures per month. 73 individuals were receiving monotherapy, 66 were treated with two AEDs and 42 were prescribed three or more AEDs at the time of the study. In those taking monotherapy, there was no difference in the mean monthly seizure frequency between groups taking different AEDs. Similarly, for those prescribed two AEDS, no particular combination was associated with significantly lower seizure frequency. One third of the sample was receiving epilepsy management from hospital neurology services but no criteria determining choice of treatment pathway were identified. The findings suggest that more research needs to be carried out to identify both optimal care pathways and AED strategies. In the light of such a limited evidence base from which to establish best practice for the management of epilepsy in those with a learning disability there is a need to describe current treatment practices and to consider the efficacy of these. The aim of this study was to collect this information from a community-based cohort of individuals with epilepsy and LD and to examine the relationships between management strategies and clinical outcomes. Such data may contribute to the optimisation of epilepsy management in this historically neglected clinical group with complex needs, both directly and by providing an evidence base to inform the development of formal clinical trials.
Method
With the support of the five Community LD Services covering one county of England we attempted to recruit all patients with epilepsy known to these services whether or not the epilepsy was itself a focus of management by the learning disability teams. The clinical teams, having identified all those with LD and epilepsy known to the teams, then approached them and their carers, asking if they would consider participating in this study. Capacity to consent was supported by participants' carers and use of visual aids and sign language and those considered to lack capacity, even with this support, were excluded from the study. The study was approved by the local NHS Research Ethics Committee. Participants were only included when there was consensus amongst the teams caring for them, based on clinical and sometimes EEG evidence that they had a diagnosis of epilepsy. The participants recruited do not represent an epidemiological sample but are rather a selected majority within each of the involved clinical services of individuals known to have LD and epilepsy.
Data were obtained retrospectively from participants' clinical notes. Data were also collected from interviews with carers, LD team members, any neurology-based clinicians involved in their management and General Practitioners. We collected data describing each patient's state over the preceding three months, including current seizure types and frequency, the nature of the clinical support and management received for the epilepsy, including current antiepileptic drugs (AEDs), current or recent co-morbid neurological and psychiatric pathologies and the nature and severity of the LD.
Results

Population ascertained
Participants were recruited from the five locality-based community adult LD services that covered one county of England with a total population of 737,900 (Office for National Statistics www.statistics.gov.uk: Mid 2004 population estimates based on the 2001 Census population). Out of 1487 individuals under the care of these teams at the time of the study a total of 183 individuals provided data for this survey, representing 12% of all the individuals with LD under the care of these teams and 71% of the total number of individuals with epilepsy and LD identified by the participating community LD teams as being under their care. The mean age of the participants was 40 years with a range of 16-72 years and 55% were male. The measure of the severity of the LD of the participants was obtained from the community teams and was based on their historical, functional and psychological assessments. Of the study population, 20% had a mild LD (IQ 70-50), 16% a moderate (IQ 50-35), 57% a severe (IQ 35-20) and 7% a profound (IQ < 20) LD. Considering the likely cause of the LD, this was unclear in 61%. The most commonly ascribed specific causes were cerebral palsy in 19% and a chromosomal disorder in 12%, most commonly Down syndrome.
Description of epilepsy within the study population
The duration of diagnosed epilepsy extended from 1 to 71 years with a mean of 26 years. Within the study population 75 individuals (41%) had epilepsy for at least 30 years. As expected, a wide range of epilepsy syndromes were manifest by the participants, with 39% described as having an idiopathic generalised epilepsy syndrome and 14% described as having symptomatic or probably symptomatic focal epilepsy. However, in 47% of the sample it was not possible to classify the nature of the epilepsy syndrome. 46% of the study population had just one type of seizure with the remainder being reported as having multiple seizure types. Considering the frequency of epileptic seizures in the study population, the mean number of seizures per month was 15, with a range of 0-559. Overall, 33% of individuals had no seizures in the three months preceding data acquisition whilst 22 (12%) had recorded an average of more than 20 seizures per month. Chisquared testing demonstrated that those with severe or profound LD were more likely to have had at least 1 seizure in the three months preceding the survey than those with less severe LD (Chisquared 12.2, df = 4, P = 0.016). There were no significant differences between the mean numbers of seizures per month reported for those with idiopathic, focal or unclassified epilepsy. Four participants were recorded as having more than 100 seizures per month of whom two had myoclonic seizures, one had myoclonic and absence seizures and one had absence seizures. After excluding these four patients, the mean number of seizures per month over the three months preceding the study was 7.2 (sd 14.1). Over the year preceding the study 85% of patients had no recorded episodes of status epilepticus whilst 8% had one episode, 3% had two episodes and 4% had three or more episodes of status.
Relationships between seizure frequencies and different antiepileptic drug regimens
The mean monthly seizure frequencies associated with different antiepileptic drug (AED) regimens are listed in Table 1 for all those regimens prescribed to at least two participants. This describes the findings from 137 individuals and excludes the data from the four individuals who had more than 100 seizures per month. Considering the study sample overall, two patients were not taking any AEDs, 73 were receiving monotherapy, 66 were being treated with two AEDs and 42 were prescribed three or more AEDs at the time of the study.
i. There was no significant difference between the numbers of AEDs prescribed to those with idiopathic, focal or unclassified epilepsy. ii. As noted above, 33% of the study population had no seizures in the three month period considered in the study. It can be seen from Table 2 that each of the three most commonly prescribed monotherapy regimens (carbamazepine, lamotrigine or sodium valproate) was given in approximately equal proportions to those with and without ongoing seizures. iii. Considering the monotherapy regimens (Table 1) , there was no difference in mean monthly seizure frequency with respect to which AED was prescribed (carbamazepine, lamotrigine, phenobarbitone, phenytoin, sodium valproate) (non-parametric Kruskal Wallis test P = 0.741). iv. Those receiving monotherapy tended to have a lower mean number of seizures per month than those prescribed two AEDs (3.1 (sd 11.4) versus 6.6 (sd 11.6)) but this difference did not reach significance (t = À1.8, P = 0.077). v. Considering those prescribed two AEDS (as listed in Table 1 ), no particular combination was associated with significantly lower seizure frequency than any other (non-parametric Kruskal Wallis test P = 0.512).
Delivery of epilepsy health care
Agencies involved
In the United Kingdom medical care of epilepsy in patients with a learning disability is generally available from one or more of the following parts of the National Health Service; the patient's GP, the local Learning Disability Psychiatry team, and hospitalbased neurology services. Of the patients surveyed, all of whom were ascertained on the basis of being under the care of a community Learning Disability Team for management of their LD, but not necessarily of their epilepsy, 37% received epilepsy care from a hospital-based neurology service. The patients' GP also actively contributed to their epilepsy care, in terms of initiating or changing treatments, in 63% of cases and for 6% of participants the GP was the only clinician supporting the epilepsy treatment.
Do epilepsy characteristics vary according to the services accessed?
Excluding the four patients with the greatest number of seizures, who were all seeing GP, LD and neurology services, it was observed that mean seizure frequency was not significantly different in those who were receiving epilepsy care from hospital neurology services (6.5 seizures/month) compared to those who were not (8.5 seizures/month, P = 0.358). Neither were there significant differences in mean duration of epilepsy (24 years versus 27 years) or number of different seizure types (1.6 in both instances) between those who did or did not receive neurology service management. There was, however, a significant difference between the mean number of AEDs prescribed to those whose epilepsy was only managed by LD services (1.7 AEDs) and those who also received Neurology service input (2.14 AEDs) (t = 3.257, P = 0.001). Considering the frequency with which neurology services compared to LD services prescribed individual agents, it was noted that clobazam was prescribed relatively more frequently to those receiving neurology-based AED management (x 2 6.627, df = 1, P = 0.018), whilst sodium valproate was prescribed relatively less often (x 2 5.027, df = 1, P = 0.025). The other AEDs listed in Table 3 were prescribed at approximately similar rates in LD and neurology services.
Do LD characteristics vary according to the services accessed?
There was no evidence that differences in severity of LD contributed to whether or not neurology services were involved in patients' epilepsy care. It was observed that similar proportions, of approximately one third, of both those with mild to moderate and Table 1 Mean monthly seizure frequencies associated with different antiepileptic drug regimens -for all regimens used in at least two individuals -(includes data from 137 individuals and excludes data from the 4 participants with >100 seizures per month).
AED regimen
Number of times prescribed in sample Mean monthly seizure frequency sd those with severe to profound LD received epilepsy care from neurology services.
Do comorbid psychopathology characteristics vary according to the services accessed?
A full description of the psychopathology observed in the participants reported in the current account is presented elsewhere. 7 In the current paper we address the question of whether the presence of ongoing psychiatric symptomatology affected which treating agencies participants were seeing. The prevalence of comorbid psychopathology was compared between those who were and those who were not receiving neurology services and it was observed that there were similar rates of psychopathology, of 37%, in both groups. When looking at the distribution of the four most common psychopathological presentations; depression, psychotic symptoms, challenging behaviour and self-injury (Table 4) , Chi-square analysis demonstrated a strong trend for depression to be seen more often than expected in those attending neurology services (x 2 = 3.583, df = 1, P = 0.058) and a somewhat weaker trend for challenging behaviour to be seen more often than expected in those attending LD services (x 2 = 3.075, df = 1, P = 0.079). Those with psychotic symptoms or self-injury were not relatively over-represented amongst either Neurology clinic or LD service attendees.
Do comorbid neurological conditions vary according to the services accessed?
As described above, participants were noted to have been diagnosed with a range of neurological conditions, the commonest specific diagnoses being cerebral palsy, dementia and hydrocephalus. However, it was found that 29% of those with and 34% of those without a comorbid neurological diagnosis were being treated by neurology services, demonstrating that presence of an additional neurological condition was not a factor in determining which treating agencies were involved in providing care at the time of the study.
Discussion
This study presents three main groups of findings from a community-based study of people with epilepsy and a learning disability. First, as has previously been reported, those with LD and epilepsy tend to have relatively poorly controlled seizures. Second, careful analysis of the varying AED regimens prescribed does not indicate that any particular regimen is more efficacious than any other, across the overall study sample, in reducing seizure frequency. As discussed below however, this similarity in apparent efficacy may have arisen from the fact that this patient group were already largely treatment-refractory at the time of their entry into the study. Third, whilst approximately one third of the sample were receiving epilepsy management from hospital-based neurology services at the time of the study, it was not clear what factors determined which treatment pathway individual patients followed. Each of these findings will be considered in turn.
In our study sample 67% reported ongoing seizures, which is very close to the comparable figure of 68% reported by McGrother et al. 8 Similarly, our finding of 33% with no seizures in the three months preceding our study is also close to the figure of 37% seizure freedom reported by Huber et al. 9 The rates of seizurefreedom observed in the current study of people with LD are hence consistent with previous studies and are considerably less than the 50-65% seizure freedom rate expected in the general population.
10,11
Although it is clear that epilepsy within the learning-disabled population is common and difficult to treat, a recent Cochrane review identified just 12 adequate trials reporting 761 participants, 12 concluding that the area was under-investigated and that it was not possible to comment on relative efficacy between medications, making treatment decisions difficult. A long-term retrospective study of AED efficacy on a group of people with epilepsy and LD resident in a large epilepsy centre 13 also noted that no specific regimen was clearly superior across the whole range of affected individuals. That account did however suggest that the combination of sodium valproate with lamotrigine may be a useful innovation. In the current study no particular regimen was associated with increased rates of seizure freedom. Because many of the patients in this study had a long history of uncontrolled epilepsy, those treated with the newer antiepileptic drugs will, in many cases, have been those who had already failed treatment with more established antiepileptic drugs and those who were treated with polytherapy will also have been a more resistant group. Consequently, the frequency of the seizures in those treated with more recently introduced AEDs may be more a reflection of the difficulty in treating the epilepsy and the use of these agents as second or third line therapies than an indication of the general efficacy (or lack of efficacy) of specific agents. Only around a third of the participants were maintained on monotherapy and neither monotherapy with carbamazepine, lamotrigine nor sodium valproate nor the combination of lamotrigine and sodium valproate conferred any significant advantage in terms of reduced seizure frequency. Whilst the monotherapy regimens were associated with the lowest seizure frequencies, this was predictable and is likely to have been because those whose epilepsy was most readily controlled were able to be maintained without the clinically perceived need to add in an additional AED. Considering the overall pattern of AED utilization, this has previously been considered by Moran et al. 11 in a population-based sample that included those with and without LD, although the relative proportions of these two groups were not reported. In the people investigated in the current study, who all had LD, there were some similarities and some differences in AED utilization compared to that wider survey. In common with those authors we noted that sodium valproate and carbamazepine were the most commonly prescribed agents as well as the most commonly prescribed as monotherapy. However, overall in the current LD sample monotherapy was used less often: in 40% compared to 69% in that wider population. In the current study however, whilst 43% of the participants had been diagnosed with epilepsy for at least 17 years, predating all AEDs introduced after lamotrigine, only 4% of monotherapy prescriptions were for phenytoin with 3% for phenobarbital. The comparable figures reported by Moran et al. were 24% for phenytoin and 5% for phenobarbital. These results suggest that over the years the pharmacological management of epilepsy in people with LD has been modified according to emerging changes in clinical practice recommendations. In addition to the question of which AEDs may be most usefully prescribed to this clinical group the issue of whether different care pathways would be more useful for different clinical situations remains unresolved. Although in principle it might be predicted that some patients would be better served by one care pathway whilst others might be better served by an alternative, this was not apparent in the current study. The evidence from this study suggests that there are currently no obvious criteria for determining whether the epilepsy in any particular individual with LD is managed either by the community LD team or by more specialist neurology services. Obvious factors, such as markers of epilepsy severity or the nature of associated comorbidities do not appear to play a role. However, the findings that on average more AEDs are prescribed by neurology services and that these services are also more likely to prescribe clobazam -often used as an adjunct in difficult to control clusters of seizures -suggests that those referred to neurology services may at one time have had more severe epilepsy than those treated by LD services. Unfortunately, the cross-sectional design of the study does not allow this possibility to be further explored. It is interesting to note though that at the time the study was carried out there were similar mean seizure frequencies across these two care pathways (of respectively 6.5 and 8.5 seizures/month). This may suggest that any of the current management approaches in this clinical group are unlikely to be able to achieve significantly better overall seizure control than this within the LD population. This observation is supported by the audit presented by Scheepers et al. 14 which reported that the effect of a careful treatment review in a comparable population brought the mean monthly seizure frequency down to 5.9, with 27% becoming seizure-free compared to 33% in the current study. Historically, (as noted in the UK Government White Paper-'Valuing People') 15 those with a learning disability have had difficulty in accessing the specialist health services available to the general population. Whilst in the LD population described in the current study those with more severe LD did not access specialist neurology services any less often that those with milder levels of disability, it was the case that more than 60% of individuals had their ongoing epilepsy care provided by community LD services. In the absence of clear care pathways for individuals into either of these treatment approaches, and the similar seizure frequency in both these treatment groups, it is not possible to determine whether those with LD are being disadvantaged in regard to their access to specialist neurology services. In drawing the above conclusions, several limitations to this study should be kept in mind. Overall, the study identified that an average of 17% of those under the care of LD health teams within the surveyed areas had epilepsy. This is a smaller percentage than the overall prevalence of epilepsy reported in the LD population, of 25% upwards. The study sample is not an epidemiological sample of those with LD and epilepsy. One reason for this is that responses from those with profound LD, in whom there are higher rates of epilepsy, were under-represented due to the inability to obtain consent from the great majority of this group. With respect to the interpretation of results associated with different AED regimens, because of the small numbers of prescriptions for the newest AEDs and because many of the participants had refractory epilepsy, it is not possible to draw conclusions regarding the usage patterns and likely efficacy of these agents.
The data reported here highlight several potential difficulties that need to be overcome in the development of randomised controlled trials of AEDs in those with epilepsy and LD. These include problems in identifying the epilepsy syndrome, the long duration of epilepsy, in many cases, prior to recruitment into a study of adults and the likelihood of a wide range of neurological and psychiatric comorbidities. However, it is not just the question of which AEDs may be most usefully prescribed to this clinical group that remains unresolved but also the issue of whether different care pathways would be more useful for different clinical presentations.
